SCHEMBL4144903

SCHEMBL4144903

CN(C)CCNc1ccc(-c2nc3c(C(=O)Nc4ccccc4)ccnc3[nH]2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAD52 P43351 1/20 0.46
UHRF1 Q96T88 1/20 0.46
GSK3B P49841 2/20 0.43
NPC1 O15118 3/20 0.43
RAB9A P51151 3/20 0.43
KDM4E B2RXH2 3/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
POLB P06746 1/20 0.43
PRMT5 O14744 1/20 0.41
CHRNA7 P36544 1/20 0.41
MOK Q9UQ07 1/20 0.40
AURKA O14965 1/20 0.39
AURKB Q96GD4 1/20 0.39
MMP2 P08253 1/20 0.39
MMP9 P14780 1/20 0.39
MMP8 P22894 1/20 0.39
MMP13 P45452 1/20 0.39
MCL1 Q07820 1/20 0.39
KMT2A Q03164 2/20 0.39
DHODH Q02127 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4961738 0.88 RAD52 (0.43) RAD52UHRF1GSK3BNPC1RAB9A
SCHEMBL4169235 0.86 GSK3B (0.49) RAD52UHRF1GSK3BKDM4EPOLB
SCHEMBL4152290 0.85 RAD52 (0.44) RAD52UHRF1GSK3BNPC1RAB9A
SCHEMBL4152121 0.84 GSK3B (0.53) RAD52UHRF1GSK3B
SCHEMBL4160387 0.84 RAD52 (0.43) RAD52UHRF1GSK3BNPC1RAB9A
SCHEMBL4152155 0.83 GSK3B (0.48) GSK3BPRMT5MMP2MMP9MMP8
SCHEMBL4161286 0.83 RAD52 (0.42) RAD52UHRF1GSK3BNPC1RAB9A
SCHEMBL4157285 0.83 RAD52 (0.42) RAD52UHRF1GSK3BNPC1RAB9A
SCHEMBL4147748 0.83 RAD52 (0.42) RAD52UHRF1GSK3BNPC1RAB9A
SCHEMBL4152144 0.82 GSK3B (0.60) GSK3BNPC1RAB9AKDM4ESMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same YUYU PHARMA, INC. (KR) 2009-07-02 US claimed
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same YUYU PHARMA, INC. (KR) 2009-07-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same GSK3B, GSK3A, MAP3K3 RAD52 4618/4885UHRF1 3834/4885GSK3B 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.